Loading...
GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab
Current xenogeneic mouse models cannot evaluate on-target off-tumor adverse effect, hindering the development of chimeric antigen receptor (CAR) T cell therapies for solid tumors, due to limited human/mouse cross-reactivity of antibodies used in CAR and sever graft-versus-host disease induced by adm...
Na minha lista:
| Udgivet i: | eLife |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
eLife Sciences Publications, Ltd
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7108862/ https://ncbi.nlm.nih.gov/pubmed/32228854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.49392 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|